Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib for Inflammatory Skin and Scalp Diseases in Down Syndrome
NCT07242638Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jan 2026
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abrocitinib in atopic dermatitis (AD) and alopecia areata, sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Rate of Serious Adverse Events at 60 weeks. Started Jan 2026; status: recruiting.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)alopecia areata
Beyond the preview
Go deeper on NCT07242638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07242638.